Parameters for monitoring treatment effects in CIDP with anti-MAG/SGPG IgM antibody.

Abstract

We used cycles of plasma exchange and intravenous cyclophosphamide to treat a patient who had chronic inflammatory demyelinating polyneuropathy with anti-myelin-associated glycoprotein/sulfoglucuronylparagloboside IgM antibody. After treatment, serum anti-sulfoglucuronylparagloboside IgM antibody titers were reduced significantly, and clear symptomatic improvement followed. The percentage of CD57-positive lymphocytes and natural killer cell activity had also returned to normal. Our findings indicate that serial measurements of these parameters are useful for monitoring treatment effect in this disease.

• Authors: Y Tagawa, N Yuki, A Ohnishi, K Hirata, S Hosokawa
• Journal: Muscle & nerve (Muscle Nerve) Vol. 24 Issue 5 Pg. 701-4 (May 2001) ISSN: 0148-639X [Print] United States
• PMID: 11317283 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2001 John Wiley & Sons, Inc.

Chemical References

• Antibodies, Blocking
• CD57 Antigens
• Globosides
• Immunoglobulin M
• Immunosuppressive Agents
• sulfate-3-glucuronyl paragloboside
• Cyclophosphamide

Topics

• Antibodies, Blocking (therapeutic use)
• CD57 Antigens (immunology)
• Cyclophosphamide (therapeutic use)
• Demyelinating Diseases (diagnosis, physiopathology, therapy)
• Electrodiagnosis
• Globosides (immunology)
• Humans
• Immunoglobulin M (therapeutic use)
• Immunosuppressive Agents (therapeutic use)
• Killer Cells, Natural (immunology)
• Male
• Middle Aged
• Sural Nerve (pathology)